Skip to main content

Table 5 Interaction between brain metastasis and afatinib starting dose in PFS. The interaction effect of brain metastasis and starting dose of afatinib (40 mg vs 30 mg OD) in PFS of patients shown in a multivariable model

From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

  No. of events / patients Hazard ratio
(95% CI)
p-value
Brain metastasis; starting dose 60 / 119   
 Brain mets; 40 mg   1  
 Brain mets; 30 mg   3.73 (1.45, 9.61) 0.006
 No brain mets; 40 mg   1.29 (0.57, 2.96) 0.542
 No brain mets; 30 mg   1.21 (0.45, 3.23) 0.711
   p-value of brain mets-starting dose interaction: 0.020
Amongst never smokers with exon 19 deletion or L858R mutation:
Brain metastasis; starting dose 37 / 84   
 Brain mets; 40 mg   1  
 Brain mets; 30 mg   5.23 (1.42, 19.28) 0.013
 No brain mets; 40 mg   1.67 (0.57, 4.87) 0.345
 No brain mets; 30 mg   1.10 (0.29, 4.20) 0.884
   p-value of brain mets-starting dose interaction: 0.011